Cancer survivors often face unique health challenges, including treatment-related metabolic complications such as weight gain, insulin resistance, and increased cardiovascular risk
An open-label phase 2 trial evaluating the investigational ASK1 inhibitor selonsertib (GS-4997) alone or in combination with the monoclonal antibody simtuzumab (SIM) in NASH patients with moderate-to-severe liver fibrosis (stages 2/3)
3.4 Liraglutide promotes insulin secretion in lipodystrophic mice Liraglutide, and GLP-1 agonists more broadly, have been shown to improve cell function by promoting insulin secretion, cell survival and cell proliferation ( Figure 4A )
Gao L, Huang H, Zhang L, Zhang N, Fu Y, Zhu D, et al
Comprehensive Health Assessment: We offer an in-depth evaluation prior to embarking on a weight loss plan